Diality has announced the first patient treatment in its PRESCRIBE Diality trial in partnership with aQua Research Institute and aQua Dialysis in Houston, Texas.
Diality is conducting the PRESCRIBE Diality trial under an investigational device exemption (IDE) to evaluate a home use indication for the Moda-flx haemodialysis system. The Moda-flx haemodialysis system received US Food and Drug Administration (FDA) clearance for use in professional care settings in August 2024.
“Diality’s Moda-flx haemodialysis system is unique in its ability to offer an integrated reverse osmosis (RO) system combined with dialysis flow rates (Qd) up to 600mL/min. Moda-flx addresses the gaps that exist between conventional in-centre dialysis and current home haemodialysis systems. Those gaps often force clinicians to compromise elements of dialysis care due to the limitations of their technology,” said Diality chief executive officer Osman Khawar. “We are fortunate to work with clinical partners like aQua Dialysis who are committed to supporting clinical research and home haemodialysis, and improving the dialysis experience for both patients and clinicians.”
The Moda-flx haemodialysis system is designed to empower kidney care professionals with a wide range of variable flow rates, integrated reverse osmosis water filtration, and an intuitive, easy-to-use graphical user interface. It provides clinicians the flexibility to easily customise each haemodialysis experience according to patient needs in one integrated system.
“We are excited to partner with Diality in this clinical trial with the objective of providing clinicians, patients and their caregivers improved technology options to positively impact their day to day lives,” said Ivan Ramirez, chief executive officer of aQua Research Institute and Dialysis.
